الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 136 |  |  |
| | | from | 136 | | |
Abstract
Systemic lupus erythematosus (SLE) is a chronic, multisystem and recurrent inflammatory autoimmune disease of unknown etiology that has effect on all major organ system.Hepcidin released from extra hepatic enzymatic cleavage of its prohormone prohepcidin. Prohepcidin regulation appears to be a complex signaling network. The various protein factors activate and inhibit the prohepcidin translation, thus achieving fine-tuned regulation of this peptide. Prohepcidin and its active form hepcidin can be upregulated by multiple stimuli including interleukin-6 (IL-6), IL-1α, IL-1β and iron, and bone morphogenetic proteins (BMP), especially BMP-2, BMP-4 and BMP- 9.
This study was carried on thirty patients with SLE met the American College of Rheumatology revised criteria for SLE. Twenty age and sex matched apparently healthy subjects were included in this study as a control group. Both patient and control groups were selected from the attendant of Rheumatology, Rehabilitation and Physical medicine department of Benha University Hospitals.The aim of this study was to analyze the relationship between serum prohepcidin, and SLE disease activity and to determine whether the prohepcidin could have a role in ACD occurring in SLE patients.
All patients were subjected to the following:•Full history taking, complete clinical examination.
•Locomotor system examination.
•Assessment of disease activity using SLEDAI score (Bombardier et al., 1992).
•Laboratory investigations included:
•Complete blood count, Erythrocyte sedimentation rate and C - reactive protein.
•Renal function tests: Including blood urea and serum creatinine levels.
•Complete urine analysis twenty four hour urin.•Protein creatinine ratio.
•ANA, Anti-ds DNAMeasurement of serum Prohepcidin levels by enzyme linked immunosorbant assay (ELISA).